"The MTD showed encouraging clinical activity, prolonging PFS and improving OS. Further efficacy confirmation of paxalisib 60 mg QD in newly diagnosed glioblastoma in a pivotal trial is ongoing (GBM AGILE, NCT03970447)."
Nothing has changed other than the Agile high threshold (which no one knows) which was not meet (Gee what were people expecting for what amounts to free trial) . Of course the bar was going to be high. Serious duds what did people think that Agile was just going to be a free lunch to registrations, The freebie ticket came with a high expectations of efficacy. However, if the 150 confirm what we already know (see above) many investor will be having a DUH!! moment. And realise what I know..... James is a smart dud who just got through 150 patients with little cost. Guys wait for the final results before you all go and shoot yourself in the foot.
KZA Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
